ALXO

1.0452.45%
JW

Jason W. Lettmann

CEO & Director

Mr. Jason W. Lettmann had been an Independent Director of ALX Oncology Holdings Inc. since April 2020 until September 6, 2023 and previously served as a Director from March 2015 to May 2017 also serves as it's CEO & Director of ALX Oncology Holdings Inc. since September 6, 2023. Mr. Lettmann serves on the board of Atsena Therapeutics, Inc. since December 16, 2020. Mr. Lettmann serves as Director of Tarsus Medical Inc. He has been a General Partner at Morgenthaler Management Corporation since July 16, 2009. He served as Director of Cerevance LLC. He joined Morgenthaler Management Corporation in 2009. He served as a General Partner at LSV Capital Management, LLC. He focused on Medical Device and Biopharmaceutical investments at LSV. He has many years of operating and venture experience in the life science sector. He has served as a General Partner of Lightstone Ventures since March 2012 and as a Partner at Morgenthaler Ventures, a venture capital and private equity firm, since June 2009. He had been an Independent Director of Ra Pharmaceuticals, Inc., from 2015 to June 28, 2018. He served as Chief Executive Officer at Promedior, Inc from January 2019 to February 2020. He served as a Principal at Morgenthaler Management Corporation. He served as a Vice President at Split Rock Partners, LLC, where he focused on early-stage venture investments in medical devices and the life sciences from June 2006 to June 2009. During his tenure at Split Rock Partners, he was actively involved with investments in Entellus Medical, Zyga Technologies, EBR Systems and Miramar Labs as well as ForSight Labs and The Foundry. He joined Split Rock Partners in June 2006 to 2009 in the healthcare team. He served as a Consultant with Accenture's Health and Life Science at Accenture plc, where he advised clients across the pharmaceutical, medical product and health services industries. He served as Genetic Research Analyst of University of Iowa Hospitals and Clinics. He served Genetic Research Analyst at Guidant, LLC. His previous experience includes tenure as a Summer Associate with Guidant Corporation's Compass Group in 2005 and West Coast Business Development Group and as a Genetic Research Analyst at the University of Iowa Hospitals and Clinics. He had been the Executive Chairman of Promedior, Inc. since December 2018 until April 2019. He serves as Director of Carrick Therapeutics, Ltd since October 3, 2016. He serves on the board of directors of Alexo Therapeutics. He served as Director of Vapotherm, Inc. since April 24, 2013 until November 2018. He served as Director at Second Genome, Inc. He serves on the board of FIRE1 and represents Morgenthaler on the boards of Promedior Pharmaceuticals, Spinewave, Ra Pharmaceuticals and Relievant Medsystems. He serves as Director of Lightstone Capital Management Ireland Ltd. He co-founded Yeti Medical and Relievant Medsystems and serves as its Member of the Board of Directors. During his tenure at Split Rock, he served as Board observer of Entellus Medical, Cabochon Aesthetics, Moximed, Zyga Technologies and Ardian. He co-founded Tarsus Medical and served as its Board Member. He holds an M.B.A., with distinction, from the University of Michigan's Ross School of Business and a B.A., with honors, in Psychology from the University of Iowa.

Positions